Learning Objectives

By the end of this chapter, learners will be able to:
1. Understand the bidirectional relationship between hypertension and kidney disease.
2. Identify the mechanisms by which kidney disease causes hypertension and vice versa.
3. Discuss the classification and diagnosis of hypertension in patients with kidney disease.
4. Outline the principles of antihypertensive management in various stages of CKD and in specific kidney conditions.
5. Recognize the importance of blood pressure control in slowing the progression of kidney disease and reducing cardiovascular risk.

31.1 Bidirectional Relationship Between Hypertension and Kidney Disease

Hypertension and kidney disease share a complex, bidirectional relationship. Hypertension can cause kidney damage (hypertensive nephrosclerosis), and kidney disease is a common cause of secondary hypertension. This vicious cycle accelerates the progression of both conditions, significantly increasing cardiovascular morbidity and mortality.

31.2 Mechanisms of Hypertension in Kidney Disease

Kidney disease contributes to hypertension through several mechanisms:

• Volume Expansion: Impaired sodium and water excretion by damaged kidneys leads to fluid retention and increased extracellular fluid volume, elevating blood pressure.
• Renin-Angiotensin-Aldosterone System (RAAS) Activation: Ischemia or damage to renal parenchyma can activate the RAAS, leading to increased angiotensin II (a potent vasoconstrictor) and aldosterone (promoting sodium and water retention).
• Sympathetic Nervous System (SNS) Overactivity: Chronic kidney disease is associated with increased sympathetic tone, contributing to vasoconstriction and elevated blood pressure.
• Endothelial Dysfunction: Reduced nitric oxide bioavailability and increased endothelin-1 contribute to impaired vasodilation and increased vascular resistance.
• Arterial Stiffness: Uremia and inflammation can lead to arterial stiffening, increasing pulse pressure and systolic blood pressure.
• Erythropoietin Deficiency: Anemia of CKD can lead to increased cardiac output, contributing to hypertension.

31.3 Mechanisms of Kidney Damage by Hypertension

Chronic uncontrolled hypertension damages the kidneys through:

• Glomerular Hyperfiltration and Hyperperfusion: High intraglomerular pressure damages the glomerular capillaries, leading to proteinuria and glomerulosclerosis.
• Renal Arteriolar Sclerosis: Thickening and narrowing of renal arterioles (afferent and efferent) reduce blood flow to the nephrons, causing ischemia and tubular atrophy.
• Inflammation and Fibrosis: Chronic injury triggers inflammatory and fibrotic processes, leading to interstitial fibrosis and loss of renal function.

31.4 Classification and Diagnosis of Hypertension in Kidney Disease

• Diagnosis: Based on repeated elevated blood pressure readings (typically >130/80 mmHg in CKD patients). Ambulatory blood pressure monitoring (ABPM) is often recommended to detect masked hypertension or nocturnal non-dipping.
• Classification: Hypertension in CKD can be primary (essential) hypertension exacerbated by kidney disease or secondary hypertension caused by kidney disease.

31.5 Antihypertensive Management in Kidney Disease

The primary goals of antihypertensive therapy in CKD are to:
– Slow the progression of kidney disease.
– Reduce cardiovascular morbidity and mortality.

General Principles

• Target Blood Pressure: Generally <130/80 mmHg for most CKD patients, but individualized targets may be considered based on age, comorbidities, and tolerability.
• Lifestyle Modifications: Essential components include dietary sodium restriction, weight management, regular exercise, and moderation of alcohol intake.

Pharmacological Therapy

• First-line Agents:
  • RAAS Inhibitors (ACEIs and ARBs): Recommended as first-line agents for most CKD patients, especially those with proteinuria, due to their renoprotective effects beyond blood pressure lowering. They reduce intraglomerular pressure and proteinuria. Close monitoring of serum creatinine and potassium is required upon initiation and dose escalation.
• Second-line Agents:
  • Diuretics: Thiazide diuretics are effective in early CKD. Loop diuretics (e.g., furosemide) are necessary in advanced CKD (eGFR <30 mL/min/1.73m²) due to their efficacy in fluid removal.
  • Calcium Channel Blockers (CCBs): Dihydropyridine CCBs (e.g., amlodipine) are effective for blood pressure control. Non-dihydropyridine CCBs (e.g., verapamil, diltiazem) can also reduce proteinuria but should be used cautiously with beta-blockers due to bradycardia risk.
  • Beta-blockers: Used for heart rate control, post-MI, or heart failure. Some are renally cleared and require dose adjustment.
  • Mineralocorticoid Receptor Antagonists (MRAs): (e.g., spironolactone, eplerenone) Can be used as add-on therapy for resistant hypertension, but careful monitoring for hyperkalemia is essential, especially in advanced CKD.

Management in Specific Conditions

• Diabetic Kidney Disease: RAAS inhibitors are cornerstone therapy.
• Polycystic Kidney Disease: Aggressive blood pressure control, often with RAAS inhibitors, is crucial to slow cyst growth and preserve renal function.
• Renal Artery Stenosis: Management depends on etiology (atherosclerotic vs. fibromuscular dysplasia) and severity. Revascularization may be considered in select cases, but medical management with RAAS inhibitors is often first-line.

31.6 Importance of Blood Pressure Control

Effective blood pressure control is paramount in CKD patients as it:
– Slows CKD Progression: Reduces intraglomerular hypertension and proteinuria.
– Reduces Cardiovascular Risk: Hypertension is a major risk factor for cardiovascular events, which are the leading cause of death in CKD patients.
– Preserves Organ Function: Protects other end organs from hypertensive damage.

Key Points on Hypertension and the Kidney

1. Bidirectional Relationship: Hypertension causes kidney damage, and kidney disease causes hypertension.
2. Mechanisms: Volume expansion, RAAS activation, SNS overactivity, endothelial dysfunction, arterial stiffness.
3. Diagnosis: Based on elevated BP readings; ABPM can be useful.
4. Management Goals: Slow CKD progression, reduce cardiovascular risk.
5. First-line Therapy: RAAS inhibitors (ACEIs/ARBs), especially with proteinuria.
6. Other Agents: Diuretics (thiazides for early CKD, loops for advanced), CCBs, beta-blockers, MRAs.
7. BP Target: Generally <130/80 mmHg, individualized.
8. Importance: Crucial for kidney and cardiovascular protection.

Hypertension and the Kidney Quick Guide

• Kidney-BP Cycle: They damage each other.
• RAAS Blockers First: Especially if protein in urine.
• Watch K+ & Cr: When starting RAAS inhibitors.
• Diuretics by GFR: Thiazides for good GFR, loops for low GFR.
• BP Control is Key: Protects kidneys and heart.

Diagnostic Pearls

1. Nocturnal Non-Dipping: In CKD patients, absence of the normal nocturnal blood pressure dip is a strong predictor of adverse cardiovascular and renal outcomes. Consider ABPM.
2. Resistant Hypertension: If hypertension is resistant to three or more antihypertensive agents (including a diuretic), investigate for secondary causes, especially renal artery stenosis or primary aldosteronism.
3. White Coat Hypertension: Confirm sustained hypertension with out-of-office measurements (home BP monitoring or ABPM) to avoid unnecessary treatment.

Management Pearls

4. RAAS Inhibitor Initiation: When starting ACEIs or ARBs, monitor serum creatinine and potassium within 1-2 weeks. A small rise in creatinine (<30% from baseline) is often acceptable and reflects reduced intraglomerular pressure.
5. Hyperkalemia with RAAS Inhibitors: If hyperkalemia develops, consider dietary potassium restriction, potassium binders, or dose reduction/discontinuation of the RAAS inhibitor, depending on severity.
6. Fluid Status: Always assess fluid status in hypertensive CKD patients. Volume overload is a common and treatable cause of hypertension.

Patient Education Pearls

7. Sodium Restriction: Emphasize the critical role of dietary sodium restriction in blood pressure control and fluid management for CKD patients.
8. Medication Adherence: Stress the importance of consistent medication adherence, as uncontrolled hypertension is a major driver of CKD progression.
9. Home Blood Pressure Monitoring: Encourage and educate patients on proper home blood pressure monitoring techniques to empower them in their own care.

Hypertension and Kidney Disease Pathophysiology

Diagram illustrating the complex interplay and pathophysiological mechanisms between hypertension and kidney disease.

Key Diagrams

• RAAS Pathway: Detailed diagram of the Renin-Angiotensin-Aldosterone System and its role in blood pressure regulation.
• Antihypertensive Drug Classes: Chart summarizing different classes of antihypertensive drugs, their mechanisms of action, and considerations in CKD.
• Blood Pressure Targets in CKD: Flowchart or table outlining recommended blood pressure targets based on CKD stage and proteinuria.

Question 1

Which of the following is a primary mechanism by which kidney disease contributes to hypertension?
A) Decreased sympathetic nervous system activity
B) Increased sodium and water excretion
C) Activation of the Renin-Angiotensin-Aldosterone System (RAAS)
D) Reduced arterial stiffness

Answer: C) Activation of the Renin-Angiotensin-Aldosterone System (RAAS)
Explanation: Kidney damage can lead to RAAS activation, causing vasoconstriction and fluid retention, thereby increasing blood pressure.

Question 2

Which class of antihypertensive medications is generally recommended as first-line therapy for most CKD patients, especially those with proteinuria?
A) Beta-blockers
B) Calcium Channel Blockers (CCBs)
C) Loop Diuretics
D) RAAS Inhibitors (ACEIs or ARBs)

Answer: D) RAAS Inhibitors (ACEIs or ARBs)
Explanation: ACEIs and ARBs are renoprotective and reduce proteinuria, making them first-line agents in CKD with proteinuria.

Question 3

Upon initiation of an ACE inhibitor in a CKD patient, what laboratory parameters should be closely monitored within 1-2 weeks?
A) Liver function tests and complete blood count
B) Serum creatinine and potassium
C) Blood glucose and hemoglobin A1c
D) Urine calcium and phosphorus

Answer: B) Serum creatinine and potassium
Explanation: ACEIs can cause a rise in serum creatinine (due to reduced intraglomerular pressure) and hyperkalemia, requiring close monitoring.

Question 4

Which of the following blood pressure targets is generally recommended for most patients with chronic kidney disease?
A) <140/90 mmHg
B) <130/80 mmHg
C) <120/70 mmHg
D) <150/90 mmHg

Answer: B) <130/80 mmHg
Explanation: A target of <130/80 mmHg is generally recommended for most CKD patients to slow disease progression and reduce cardiovascular risk.

Question 5

Which type of diuretic is typically preferred in patients with advanced CKD (eGFR <30 mL/min/1.73m²) for fluid management?
A) Thiazide diuretics
B) Loop diuretics
C) Potassium-sparing diuretics
D) Carbonic anhydrase inhibitors

Answer: B) Loop diuretics
Explanation: Loop diuretics maintain their efficacy even at low GFRs, unlike thiazide diuretics, which become less effective.

Question 6

Which of the following is a common mechanism by which chronic uncontrolled hypertension damages the kidneys?
A) Decreased intraglomerular pressure
B) Glomerular hyperfiltration and hyperperfusion
C) Dilation of renal arterioles
D) Increased nitric oxide production

Answer: B) Glomerular hyperfiltration and hyperperfusion
Explanation: High intraglomerular pressure due to hypertension damages glomerular capillaries, leading to injury and proteinuria.

Question 7

What is the significance of

Visual learning: Chapter 31: Hypertension and the Kidney – Complete Educational Package

Presentation resource: The Kidney Hub clinical-series PowerPoint for Chapters 31–40 accompanies these chapters for teaching use.